ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 308

Next-Generation Sequencing of Urinary Microrna in Human Lupus Nephritis

Beatrice Goilav1, Iddo Z. Ben-Dov2, Irene Blanco3, Olivier Loudig4, Dawn M. Wahezi5 and Chaim Putterman6, 1Division of Nephrology, Children's Hospital at Montefiore, Bronx, NY, 2Laboratory of RNA Molecular Biology, The Rockefeller University, New York, NY, 3Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 4Epidemiology, Albert Einstein College of Medicine, Bronx, NY, 5Pediatric Rheumatology, Children's Hospital Montefiore, Bronx, NY, 6Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, Epigenetics, lupus nephritis and pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Lupus nephritis (LN) is a common manifestation of SLE associated with significant morbidity and mortality. microRNAs (miRs) are small non-coding RNAs that regulate translation and mRNA stability. Preliminary studies have reported changes in miR expression in kidney tissue, urine, and PBMC that correlated with disease activity in LN. However, use of RNA deep-sequencing methods has not been previously described. We aimed at identifying miR expression patterns in LN by RNA sequencing.

Methods: Cell-free urine supernatants from adult (n=9) and pediatric (n=4) female patients with LN were obtained at the time of active disease and during remission. Total RNA was used to prepare small RNA cDNA libraries for Illumina sequencing. Multiplexing through sample-specific 3′ adapters (“bar coding”) was applied to limit batch effects, labor and cost. Sequenced reads were mapped to the human genome and small RNA databases, and miRs were quantified by relative read abundance. qRT-PCR was used for quantitative validation of sequencing results.

Results: We were able to obtain reproducible profiles of miRNA from the small RNA fraction. In a paired-sample analysis comparing the number of miR sequence reads in urine of active versus inactive LN, we found significant upregulation of multiple miRNAs, including -185, -328, -378, -874, and -423. In total, we found differential expression of ~19 miRs during active nephritis. A subset analysis revealed 13 miRs that were upregulated by a 400-1,000 fold change during active disease in pediatric, but not in adult samples. Differential expression of several miRs was confirmed by miRNA qRT-PCR.

Conclusion: In summary, we detected a group of miRs (most of which have not been previously described in lupus) with significantly higher presence in the urine during active LN, particularly, in pediatric patients. These miRs may represent biomarkers for disease activity or indicators of specific histologic features. Several urine miRs were previously found to be differentially expressed in immune cells, which may imply that their presence in urine originates from infiltrating rather than kidney resident cells. Finally, upregulated miRs during active LN could imply that their “protective” target genes are repressed in relapse, and that identifying the latter may reveal novel therapeutic pathways in this challenging disease.


Disclosure:

B. Goilav,
None;

I. Z. Ben-Dov,
None;

I. Blanco,
None;

O. Loudig,
None;

D. M. Wahezi,
None;

C. Putterman,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/next-generation-sequencing-of-urinary-microrna-in-human-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology